SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9313)3/21/1999 10:44:00 PM
From: aknahow  Respond to of 17367
 
Old but interesting, from June 20, 1997.

Another member of this protein family, LBP
(lipopolysaccharide-binding protein), also plays a role in the
body's inflammatory response to infection. In contrast to BPI's
endotoxin-inactivating role, however, LBP binds to endotoxin
and triggers the inflammatory response. The remaining two
molecules in this family are phospholipid transfer protein
(PLTP) and cholesterol ester transfer protein (CETP). CETP
may play a role in atherosclerosis, because it carries cholesterol
to the liver and mediates the conversion of high density
lipoproteins (HDL) to low density lipoproteins (LDL).



To: Cacaito who wrote (9313)3/27/1999 9:14:00 AM
From: StockDoc  Read Replies (1) | Respond to of 17367
 
"StockDoc, one will need 20,000 patients, to prove a 10%
improvement in the Bpi arm if one assumes a 10% mortality. 10%
improvement means:
placebo 10%, bpi 9% (1% is the 10% improvement of 10%)."

How about an astonishing 50% improvement (i.e., 10 to 5%)?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News